{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:39:11Z","timestamp":1792813151044,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1038\/s41409-019-0498-0","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T17:04:15Z","timestamp":1551719055000},"page":"1662-1667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin\u2019s Lymphoma"],"prefix":"10.1038","volume":"54","author":[{"given":"Tobias A. W.","family":"Holderried","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Fraccaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annkristin","family":"Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brossart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Klobuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petya","family":"Apostolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4049-7854","authenticated-orcid":false,"given":"Thomas","family":"Heinicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"key":"498_CR1","first-page":"2230","volume":"29","author":"JR Wingard","year":"2011","unstructured":"Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic. Cell Transplant JCO. 2011;29:2230\u20139.","journal-title":"Cell Transplant JCO"},{"key":"498_CR2","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3389\/fimmu.2017.00496","volume":"8","author":"AM Dickinson","year":"2017","unstructured":"Dickinson AM, Norden J, Li S, Hromadnikova I, Schmid C, Schmetzer H, et al. Graft-versus-leukemia effect following hematopoietic stem cell transplantation for leukemia. Front Immunol. 2017;8:832.","journal-title":"Front Immunol"},{"key":"498_CR3","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1200\/JCO.2016.71.0806","volume":"35","author":"JA Kennedy","year":"2017","unstructured":"Kennedy JA, Ebert BL. Clinical implications of genetic mutations in myelodysplastic syndrome. JCO. 2017;35:968\u201374.","journal-title":"JCO"},{"key":"498_CR4","doi-asserted-by":"publisher","unstructured":"Hutten TJA, Norde WJ, Woestenenk R, Wang RC, Maas F, Kester M, et al. Increased coexpression of PD-1, TIGIT, and KLRG-1 on tumor-reactive CD8+ T cells during relapse after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2017. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2017.11.027\n                    \n                  .","DOI":"10.1016\/j.bbmt.2017.11.027"},{"key":"498_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11864-017-0476-y","volume":"18","author":"C Ramamurthy","year":"2017","unstructured":"Ramamurthy C, Godwin JL, Borghaei H. Immune checkpoint inhibitor therapy: what line of therapy and how to choose? Curr Treat Options Oncol. 2017;18:33.","journal-title":"Curr Treat Options Oncol"},{"key":"498_CR6","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1182\/blood-2017-10-752154","volume":"131","author":"RJ Soiffer","year":"2018","unstructured":"Soiffer RJ, Davids MS, Chen Y-B. Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Blood. 2018;131:1073\u201380.","journal-title":"Blood"},{"key":"498_CR7","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI94196","volume":"127","author":"TV Brennan","year":"2017","unstructured":"Brennan TV, Yang Y. PD-L1 serves as a double agent in separating GVL from GVHD. J Clin Invest. 2017;127:1627\u201330.","journal-title":"J Clin Invest"},{"key":"498_CR8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/bmt.2015.346","volume":"51","author":"JA Yared","year":"2016","unstructured":"Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M, et al. Major clinical response to nivolumab in relapsed\/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:850\u20132.","journal-title":"Bone Marrow Transplant"},{"key":"498_CR9","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","volume":"129","author":"C Herbaux","year":"2017","unstructured":"Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129:2471\u20138.","journal-title":"Blood"},{"key":"498_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","volume":"130","author":"BM Haverkos","year":"2017","unstructured":"Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, et al. PD-1 blockade for relapsed lymphoma post\u2013allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130:221\u20138.","journal-title":"Blood"},{"key":"498_CR11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/bmt.2016.346","volume":"52","author":"E McDuffee","year":"2017","unstructured":"McDuffee E, Aue G, Cook L, Ramos-Delgado C, Shalabi R, Worthy T, et al. Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52:759\u201361.","journal-title":"Bone Marrow Transplant"},{"key":"498_CR12","doi-asserted-by":"publisher","first-page":"eaam7729","DOI":"10.1126\/scitranslmed.aam7729","volume":"10","author":"A Prestipino","year":"2018","unstructured":"Prestipino A, Emhardt AJ, Aumann K, O\u2019Sullivan D, Gorantla SP, Duquesne S, et al. Oncogenic JAK2V617Fcauses PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med. 2018;10:eaam7729.","journal-title":"Sci Transl Med"},{"key":"498_CR13","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","volume":"113","author":"A Bashey","year":"2009","unstructured":"Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113:1581\u20138.","journal-title":"Blood"},{"key":"498_CR14","doi-asserted-by":"publisher","unstructured":"Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375:143\u201353. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1601202\n                    \n                  .","DOI":"10.1056\/NEJMoa1601202"},{"key":"498_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/bmt.2016.274","volume":"52","author":"JC Albring","year":"2017","unstructured":"Albring JC, Inselmann S, Sauer T, Schliemann C, Altvater B, Kailayangiri S, et al. PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. Bone Marrow Transplant. 2017;52:317\u201320.","journal-title":"Bone Marrow Transplant"},{"key":"498_CR16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.bmt.1700778","volume":"19","author":"S Dermime","year":"1997","unstructured":"Dermime S, Mavroudis D, Jiang YZ, Hensel N, Molldrem J, Barrett AJ. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19:989\u201399.","journal-title":"Bone Marrow Transplant"},{"key":"498_CR17","doi-asserted-by":"publisher","unstructured":"Zeiser R, Vago L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood 2018. \n                    https:\/\/doi.org\/10.1182\/blood-2018-10-846824\n                    \n                  .","DOI":"10.1182\/blood-2018-10-846824"},{"key":"498_CR18","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, et al. Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med. 2018;379:2330\u201341.","journal-title":"N Engl J Med"},{"key":"498_CR19","doi-asserted-by":"publisher","unstructured":"Koyama D, Murata M, Hanajiri R, Akashi T, Okuno S, Kamoshita S, et al. Quantitative assessment of T cell clonotypes in human acute graft-versus-host disease tissues. Biol Blood Marrow Transplant 2018. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2018.10.012\n                    \n                  .","DOI":"10.1016\/j.bbmt.2018.10.012"},{"key":"498_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3389\/fimmu.2018.02547","volume":"9","author":"AS Gkazi","year":"2018","unstructured":"Gkazi AS, Margetts BK, Attenborough T, Mhaldien L, Standing JF, Oakes T, et al. Clinical T cell receptor repertoire deep sequencing and analysis: an application to monitor immune reconstitution following cord blood transplantation. Front Immunol. 2018;9:575.","journal-title":"Front Immunol"},{"key":"498_CR21","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/bmt.2015.133","volume":"50","author":"PY Yew","year":"2015","unstructured":"Yew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, et al. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015;50:1227\u201334.","journal-title":"Bone Marrow Transplant"},{"key":"498_CR22","doi-asserted-by":"publisher","unstructured":"Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, et al. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. JCI Insight 2018;3. \n                    https:\/\/doi.org\/10.1172\/jci.insight.122092\n                    \n                  .","DOI":"10.1172\/jci.insight.122092"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0498-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0498-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0498-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:14:22Z","timestamp":1684617262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-019-0498-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,4]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["498"],"URL":"https:\/\/doi.org\/10.1038\/s41409-019-0498-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,4]]},"assertion":[{"value":"29 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}